secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arbutus Biopharma Corp (ABUS)
CIK:        0001447028
Form:       8-K
Filed at:   2022-10-24T23:59:59+00:00
Accession:  0001447028-22-000051
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arbutus Biopharma appoints Mike McElhaugh as COO effective Nov 1, 2022; salary to $460,000
--------------------------------------------------------------------------------

- Mike McElhaugh promoted from Chief Business Officer to Chief Operating Officer, effective November 1, 2022.
- Annual base salary increased to $460,000 under third amendment to existing employment agreement.
- McElhaugh has been with Arbutus since 2014 and was a co-founder of OnCore Biopharma acquired by Arbutus in 2015.
- No other changes to employment terms; no family relationships or transactions requiring disclosure.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447028/000144702822000051/0001447028-22-000051-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447028/000144702822000051/abus-20221018.htm
  HTML page:      https://secwatch.observer/filing/0001447028-22-000051

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer